Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Pfizer sells site to generics firm

January 28, 2008 | A version of this story appeared in Volume 86, Issue 4

Pfizer is selling its pharmaceutical manufacturing plant in Nerviano, Italy, to Actavis, the Icelandic generic drug company. The plant, which employs around 340 people, specializes in the manufacture of oncology products. Actavis CEO Robert Wessman says the facility will help his company meet growth projections for its oncology portfolio. Separately, Actavis has entered a multiyear agreement with Pfizer for the supply of oncology products.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.